FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Alli (seen in more than 1 patient in 10) are oily spotting, flatus (gas) with discharge, faecal urgency (urgent need to open the bowels), fatty oily stool, oily evacuation (bowel movements of just oil, without stool), flatulence (gas) and soft stools.
Slovenian: Najpogostejši neželeni učinki zdravila Alli (opaženi pri več kot 1 od 10 bolnikov) so oljni madeži, flatus (vetrovi) z uhajanjem, nujnost odvajanja (nujna potreba po izpraznitvi črevesa), mastno ali oljnato blato, oljnato odvajanje (odvajanje samo olja, brez blata), flatulenca (vetrovi) in mehko blato.
English: Alli is a medicine that contains the active substance orlistat.
Slovenian: Alli je zdravilo, ki vsebuje zdravilno učinkovino orlistat.
English: Because Alli is based on another medicine containing the same active substance already authorised in the EU (Xenical 120 mg capsules), some of the studies involved patients who took Xenical.
Slovenian: Ker je osnova za zdravilo Alli drugo zdravilo, ki vsebuje enako zdravilno učinkovino in je že odobreno v EU (zdravilo Xenical, 120 mg, kapsule), so bili v nekatere študije vključeni bolniki, ki so jemali zdravilo Xenical.
English: It must not be used in people who are being treated with ciclosporin (used to prevent organ rejection in transplant patients) or with medicines used to prevent blood clots such as warfarin.
Slovenian: Ne smejo ga uporabljati osebe, ki se zdravijo s ciklosporinom (ki se uporablja proti zavrnitvi organov pri bolnikih, pri katerih je bila opravljena presaditev) ali z zdravili za preprečevanje nastanka krvnih strdkov, kot je na primer varfarin.
English: The company also carried out studies to show that Alli 27 mg chewable tablets have the same effect on fat absorption as Alli 60 mg capsules.
Slovenian: Družba je študije izvedla tudi zato, da pokaže, da imajo 27-miligramske žvečljive tablete enak učinek na absorpcijo maščobe kot 60-miligramske kapsule zdravila Alli.
English: When these enzymes are blocked, they cannot digest some fats in the diet, and this allows about a quarter of the fat eaten in the meal to be passed out in the stools undigested.
Slovenian: Če so ti encimi blokirani, ne morejo prebaviti dela maščob, zaradi česar se približno četrtina maščob, zaužitih z hrano, neprebavljenih izloči z blatom.
English: Why has Alli been approved?
Slovenian: Zakaj je bilo zdravilo Alli odobreno?
English: Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Alli.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Alli, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Orlistat blocks gastrointestinal lipases (enzymes that digest fat).
Slovenian: Orlistat zavira lipaze v prebavilih (encime, ki prebavljajo maščobo).
English: It is used in adults who are overweight with a body mass index (BMI) greater than or equal to 28 kg per square metre, in combination with a low calorie diet with reduced fat levels.
Slovenian: Uporablja se pri odraslih s čezmerno telesno maso, katerih indeks telesne mase (ITM) je večji ali enak 28 kg na kvadratni meter, ob hkratni nizkokalorični dieti z zmanjšanim vnosom maščob.
English: Alli must not be used in people who are hypersensitive (allergic) to orlistat or any of the other ingredients.
Slovenian: Zdravila Alli ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) orlistat ali katero koli drugo sestavino zdravila.
English: The active substance in Alli, orlistat, is an anti-obesity medicine, which does not affect appetite.
Slovenian: Zdravilna učinkovina zdravila Alli, orlistat, je zdravilo proti debelosti, ki ne vpliva na tek.
English: If a meal is missed or contains no fat, Alli should not be taken.
Slovenian: Če bolnik obrok izpusti ali če ta ne vsebuje maščob, naj bolnik zdravila Alli ne vzame.
English: If patients taking Alli have been unable to lose weight after 12 weeks, they should speak to their doctor or pharmacist.
Slovenian: Če bolniki, ki jemljejo zdravilo Alli, po 12 tednih zdravljenja niso uspeli zmanjšati telesne mase, naj se pogovorijo z zdravnikom ali farmacevtom, saj bo morda treba zdravljenje prekiniti.
English: Most of the side effects with Alli affect the digestive system and are less likely to occur with a low fat diet.
Slovenian: Večina neželenih učinkov zdravila Alli je povezanih s prebavnim sistemom, njihov pojav pa je manj verjeten pri dietah z malo maščobami.
English: It must also not be used in people with chronic malabsorption syndrome (a long-term disease where nutrients from food are not easily absorbed during digestion) or cholestasis (a liver disorder), or in women who are pregnant or breast-feeding.
Slovenian: Prav tako ga ne smejo uporabljati osebe s kroničnim malabsorpcijskim sindromom (dolgotrajno boleznijo, pri kateri se hranilne snovi iz hrane med prebavljanjem ne absorbirajo zlahka), osebe s holestazo (motnjo delovanja jeter) ali doječe matere.
English: In the two studies of patients with a BMI of 28 kg/m2 or more, patients taking Alli 60 mg capsules had lost an average of 4.8 kg after a year, compared with 2.3 kg in those taking placebo.
Slovenian: Študiji bolnikov, pri katerih je ITM znašal 28 kg/m2 ali več, sta pokazali, da so bolniki, ki so jemali zdravilo Alli v obliki 60-miligramskih kapsul, po enem letu v povprečju izgubili 4,8 kg v primerjavi z 2,3 kg pri tistih, ki so jemali placebo.
English: For the full list of all side effects reported with Alli, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Alli, glejte navodilo za uporabo.
English: The third study compared Alli with placebo in 391 overweight patients with a BMI between 25 and 28 kg/m2.
Slovenian: V tretji študiji so zdravilo Alli primerjali s placebom pri 391 bolnikih s čezmerno telesno maso, pri katerih je ITM znašal med 25 in 28 kg/m2.
English: What is Alli used for?
Slovenian: Za kaj se zdravilo Alli uporablja?
English: The study of Alli in patients with a BMI between 25 and 28 kg/m2 failed to show a degree of weight loss that would be relevant for patients.
Slovenian: V študiji zdravila Alli pri bolnikih z ITM med 25 in 28 kg/m2 ni bilo doseženo takšno zmanjšanje telesne mase, ki bi bilo pomembno za bolnike.
English: The studies comparing the chewable tablets with the capsules showed that the amount of undigested fat passed out in patients' stools was the same after taking either formulation.
Slovenian: V študijah, v katerih so primerjali žvečljive tablete s kapsulami, so bolniki po jemanju ene in druge formulacije v blatu izločili enako količino neprebavljene maščobe.
English: How has Alli been studied?
Slovenian: Kako je bilo zdravilo Alli raziskano?
English: Alli is used to help patients lose weight.
Slovenian: Zdravilo Alli bolnikom pomaga pri zmanjševanju telesne mase.
English: How is Alli used?
Slovenian: Kako se zdravilo Alli uporablja?
English: Alli was more effective than placebo in reducing weight in patients with a BMI of 28 kg/m2 or more.
Slovenian: Zdravilo Alli je bilo pri zmanjševanju telesne mase pri bolnikih z ITM 28 kg/m2 ali več učinkovitejše od placeba.
English: What is Alli?
Slovenian: Kaj je zdravilo Alli?
English: How does Alli work?
Slovenian: Kako zdravilo Alli deluje?
English: Two of the studies involving a total of 1,353 overweight or obese patients with a BMI of 28 kg/m2 or more and lasted from one to two years, comparing Alli given at different doses with placebo (a dummy treatment), in combination with dieting.
Slovenian: V dveh študijah, ki sta trajali od enega do dveh let, je sodelovalo skupaj 1 353 bolnikov s prekomerno telesno maso ali debelih bolnikov, pri katerih je ITM znašal 28 kg/m2 ali več.
English: • under 18 years old;
Slovenian: • osebe, mlajše od 18 let;
English: Generally, one vial is sufficient, but a further vial can be used if necessary.
Slovenian: Običajno zadošča ena viala, vendar pa je po potrebi mogoče uporabiti še eno.
English: Osigraft must also not be used by the following groups of patients:
Slovenian: Zdravila Osigraft ne smejo uporabljati naslednje skupine bolnikov:
English: The main measure of effectiveness, which was assessed after nine months, was whether the broken bone had healed.
Slovenian: Glavno merilo učinkovitosti, ki so jo ocenjevali po devetih mesecih, je bilo, ali se je zlomljena kost zacelila.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Osigraft to Howmedica International S. de R. L. on 17 May 2001.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Osigraft, veljavno po vsej Evropski uniji, odobrila družbi Howmedica International S. de R. L. dne 17. maja 2001.
English: Other information about Osigraft
Slovenian: Druge informacije o zdravilu Osigraft
English: • with an active infection at the surgery site or another serious infection;
Slovenian: • osebe z aktivno okužbo na območju kirurškega posega ali drugo resno okužbo;
English: The full EPAR for Osigraft can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Osigraft je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • with an autoimmune disease (where the immune system attacks parts of the body);
Slovenian: • osebe z avtoimunsko boleznijo (pri katerih imunski sistem napada dele telesa);
English: It is used in skeletally mature patients (who have stopped growing).
Slovenian: Uporablja se pri bolnikih z zrelim okostjem (ki so prenehali rasti).
English: The replacement eptotermin alfa acts in same way as naturally produced BMP-7.
Slovenian: Nadomestni eptotermin alfa deluje na enak način kot naravno proizvedeni BMP-7.
English: It is a copy of a protein called osteogenic protein 1, also known as bone morphogenetic protein 7 (BMP-7), that is produced naturally by the body and which helps the formation of new bone tissue.
Slovenian: Je kopija proteina, imenovanega osteogeni protein 1, znanega tudi kot morfogenetski protein 7 (BMP-7), ki naravno nastaja v telesu in spodbuja tvorbo novega kostnega tkiva.
English: What benefit has Osigraft shown during the studies?
Slovenian: Kakšne koristi je zdravilo Osigraft izkazalo med študijami?
English: After nine months, 81% of the patients receiving Osigraft had responded to treatment (less pain and more weight bearing), compared with 77% of the patients treated with an autograft.
Slovenian: Po devetih mesecih se je na zdravljenje odzvalo 81 % bolnikov, ki so prejeli zdravilo Osigraft (zmanjšanje bolečin in povečana zmožnost obremenitve golenice), v primerjavi s 77 % bolnikov, ki so bili zdravljeni z avtolognim presadkom.
English: For more information about treatment with Osigraft, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Osigraft preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Osigraft.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Osigraft.
English: The main study of Osigraft was carried out in 122 patients with unhealed tibial fractures who were treated either with the medicine or with an autograft.
Slovenian: Glavna študija zdravila Osigraft je bila izvedena pri 122 bolnikih z nezaceljenim zlomom golenice, ki so bili zdravljeni bodisi z zdravilom Osigraft ali z avtolognim presadkom.
English: • receiving chemotherapy, radiation treatment or immunosuppression.
Slovenian: • osebe, ki prejemajo kemo-, radio- ali imunosupresivno terapijo.
English: Immediately before use, Osigraft is mixed with 2 to 3 ml of sodium chloride solution to make up a suspension that has the consistency of wet sand.
Slovenian: Neposredno pred uporabo se zdravilo Osigraft zmeša z 2 do 3 ml raztopine natrijevega klorida, s čemer dobimo suspenzijo s konsistenco mokrega peska.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Osigraft.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Osigraft, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The most common side effects with Osigraft (seen in between 1 and 10 patients in 100) are erythema (redness), tenderness, swelling over the implant site, heterotopic ossification (development of bone in abnormal areas) or myositis ossificans (abnormal bone growth in the muscle), and the formation of antibodies against eptotermin alfa.
Slovenian: Najpogostejši neželeni učinki (opaženi pri 1 do 10 bolnikih izmed 100) so eritem (pordelost), občutljivost, zatekanje na mestu vsadka, heterotopična okostenitev (tvorba kostnine zunaj mesta zloma) ali osificirajoči miozitis (nenormalna rast kosti v mišico) ter tvorba protiteles proti eptoterminu alfa.
English: The CHMP decided that Osigraft's benefits are greater than its risks and recommended that Osigraft be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Osigraft večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: • with a tumour near the fracture;
Slovenian: • osebe s tumorjem v bližini mesta zloma;
English: • where the fracture is disease-related (such as metabolic bone disease or cancer);
Slovenian: • osebe, pri katerih je zlom povezan z boleznijo (npr. presnovnimi boleznimi ali rakom);
English: This was detected by looking at signs of repair of the fracture on an X-ray, whether the patient had any pain and was able to bear weight on the tibia, and whether there was any need for further treatment of the fractured tibia.
Slovenian: To so ugotavljali s preverjanjem znakov zacelitve zloma na rentgenski sliki ter ugotavljanjem, ali ima bolnik bolečine in ali lahko obremeni golenico, kakor tudi s preverjanjem, ali obstaja potreba po nadaljnjem zdravljenju zloma.
English: What is the risk associated with Osigraft?
Slovenian: Kakšna tveganja so povezana z zdravilom Osigraft?
English: The surrounding soft tissues, such as muscle and skin, are then closed around the implant.
Slovenian: Zatem se okrog vsadka zaprejo obkostna mehka tkiva, kot so mišice in koža.
English: Eptotermin alfa is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA), which makes them able to produce it.
Slovenian: Eptotermin alfa je izdelan z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori eptotermin alfa.
English: This mixture is then placed by the surgeon directly at the fracture site in contact with the prepared broken bone ends.
Slovenian: To mešanico kirurg nato nanese neposredno na mesto zloma v stiku s pripravljeno površino obeh koncev zlomljene kosti.
English: Osigraft should not be used in people who may be hypersensitive (allergic) to eptotermin alfa or to collagen.
Slovenian: Zdravila Osigraft ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) eptotermin alfa ali kolagen.
English: Osigraft was at least as effective as bone autograft, the standard treatment.
Slovenian: Zdravilo Osigraft je bilo vsaj tako učinkovito kot avtologni presadek kosti, ki predstavlja standardno obliko zdravljenja.
English: • skeletally immature (still growing);
Slovenian: • osebe z nezrelim okostjem (ki še rastejo);
English: Osigraft should be used by a qualified surgeon.
Slovenian: Zdravilo Osigraft sme uporabljati le ustrezno usposobljen kirurg.
English: Osigraft is used to repair fractures of the tibia (shin bone) that have not healed after at least nine months.
Slovenian: Zdravilo Osigraft se uporablja za zdravljenje zlomov golenice, ki se po najmanj devetih mesecih še niso zacelili.
English: For the full list of all side effects reported with Osigraft, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Osigraft, glejte navodilo za uporabo.
English: Why has Osigraft been approved?
Slovenian: Zakaj je bilo zdravilo Osigraft odobreno?
English: It is used in patients who have previously had an autograft (a bone graft taken from their own bone, usually the hip) that has failed or when such a graft is not possible.
Slovenian: Uporablja se pri bolnikih, ki so bili predhodno neuspešno zdravljeni z avtolognim presadkom (kostnim presadkom, pridobljenim iz njihove lastne kosti, običajno kolka), ali pri bolnikih pri katerih avtologno presajanje ni izvedljivo.
English: Osigraft is a powder to be made up into a suspension for implantation.
Slovenian: Zdravilo Osigraft je prašek za pripravo suspenzije za implantacijo.
English: When implanted, eptotermin alfa stimulates the formation of new bone, helping to repair the broken bone.
Slovenian: Ko je eptotermin alfa vsajen, spodbuja tvorbo nove kostnine, kar prispeva k celjenju zlomljene kosti.
English: The active substance in Osigraft, eptotermin alfa, acts on the bone structure.
Slovenian: Zdravilna učinkovina v zdravilu Osigraft, eptotermin alfa, učinkuje na strukturo kosti.
English: It contains the active substance eptotermin alfa.
Slovenian: Vsebuje zdravilno učinkovino eptotermin alfa.
English: • without enough skin or blood supply at the fracture site;
Slovenian: • osebe, pri katerih mesto zloma ni ustrezno pokrito s kožo ali dovolj prekrvavljeno;
English: What is Osigraft used for?
Slovenian: Za kaj se zdravilo Osigraft uporablja?
English: How has Osigraft been studied?
Slovenian: Kako je bilo zdravilo Osigraft raziskano?
English: How is Osigraft used?
Slovenian: Kako se zdravilo Osigraft uporablja?
English: What is Osigraft?
Slovenian: Kaj je zdravilo Osigraft?
English: How does Osigraft work?
Slovenian: Kako zdravilo Osigraft deluje?
English: Where necessary, treatment can be repeated every twelve weeks.
Slovenian: Po potrebi se lahko zdravljenje ponovi vsakih dvanajst tednov.
English: Further information on Bravecto Plus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/bravecto-plus.
Slovenian: Nadaljnje informacije o zdravilu Bravecto Plus so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/bravecto-plus.
English: Bravecto Plus received a marketing authorisation valid throughout the EU on 8 May 2018.
Slovenian: Zdravilo Bravecto Plus je pridobilo dovoljenje za promet, veljavno po vsej EU, 8. maja 2018.
English: This results in paralysis and death of the parasites.
Slovenian: To povzroči paralizo in smrt parazitov.
English: The European Medicines Agency decided that Bravecto Plus's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je odločila, da so koristi zdravila Bravecto Plus večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Bravecto Plus (fluralaner / moxidectin)
Slovenian: Bravecto Plus (fluralaner/moksidektin)
English: For ear mite infestations, a veterinary check is necessary 28 days after treatment.
Slovenian: Za zdravljenje infestacij z ušesnimi garjami je potreben veterinarski pregled 28 dni po zdravljenju.
English: Fluralaner acts as an ‘ectoparasiticide'.
Slovenian: Fluralaner deluje kot „ektoparaziticid“.
English: This medicine is harmful if swallowed.
Slovenian: Zdravilo je škodljivo pri zaužitju.
English: Other information about Bravecto Plus
Slovenian: Druge informacije o zdravilu Bravecto Plus
English: Contact with the application site should be avoided until it is no longer noticeable.
Slovenian: Stiku z mestom nanosa se je treba izogibati, dokler ni več opazno.
English: In case of skin contact, the affected area should be rinsed immediately with soap and water whilst in case of eye contact, the affected area should be rinsed immediately with water.
Slovenian: V primeru stika s kožo je treba prizadeto območje takoj izprati z milom in vodo, v primeru stika z očmi je treba prizadeto območje takoj izprati z vodo.
English: Fluralaner kills fleas before they can lay eggs and so helps to reduce contamination of the cats' environment.
Slovenian: Fluralaner ubije bolhe, preden izležejo jajčeca, s čimer pomaga zmanjšati kontaminacijo okolice mačke.
English: The medicine should be kept in the original package until use, in order to prevent children directly accessing the medicine.
Slovenian: Do uporabe ga je treba shranjevati v originalni ovojnini, da se otrokom prepreči neposreden stik z njim.
English: What are the risks associated with Bravecto Plus?
Slovenian: Kakšna tveganja so povezana z zdravilom Bravecto Plus?
English: What benefits of Bravecto Plus have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Bravecto Plus izkazalo v študijah?
English: Bravecto Plus kills fleas and ticks within 48 hours.
Slovenian: Zdravilo Bravecto Plus ubije bolhe in klope v 48 urah.
English: What is Bravecto Plus and what is it used for?
Slovenian: Kaj je zdravilo Bravecto Plus in za kaj se uporablja?
English: The most common side effects with Bravecto Plus (which may affect up to 1 in 10 animals) are mild and short-lived reactions at the application site such as hair loss, flaking skin and scratching.
Slovenian: Najpogostejši neželeni učinki zdravila Bravecto Plus (ki lahko prizadenejo največ 1 žival od 10) so blage in kratkotrajne reakcije na mestu nanosa, kot so izguba dlak, luščenje kože in praskanje.
English: Moxidectin causes paralysis and death of these parasites by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites' nervous system.
Slovenian: Moksidektin povzroči paralizo in smrt teh parazitov tako, da ovira prenos signalov med živčnimi celicami (živčni prenos) v njihovem živčevju.
English: For more information about using Bravecto Plus, see the package leaflet or contact your veterinarian or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Bravecto Plus glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
English: An overview of Bravecto Plus and why it is authorised in the EU
Slovenian: Pregled zdravila Bravecto Plus in zakaj je odobreno v EU
English: Why is Bravecto Plus authorised in the EU?
Slovenian: Zakaj je zdravilo Bravecto Plus odobreno v EU?
English: Fluralaner kills fleas and ticks that have ingested the cat's blood by causing uncontrolled activity of their nervous system.
Slovenian: Fluralaner ubije bolhe in klope, ki so zaužili mačkino kri, tako da povzroči nenadzorovano delovanje njihovega živčnega sistema.
English: Bravecto Plus is a veterinary medicine used in cats to treat mixed infestations with both ticks or fleas and ear mites and/or worms that live inside the body.
Slovenian: Bravecto Plus je zdravilo za uporabo v veterinarski medicini, ki se uporablja pri mačkah za zdravljenje mešanih infestacij s klopi ali bolhami ter ušesnimi garjami in/ali črvi, ki živijo v telesu.
English: Bravecto Plus was as effective as another medicine containing emodepside and praziquantel.
Slovenian: Zdravilo Bravecto Plus je bilo enako učinkovito kot drugo zdravilo, ki je vsebovalo emodepsid in prazikantel.
English: Fluralaner and moxidectin are already authorised on their own for the treatment of parasitic infestations.
Slovenian: Fluralaner in moksidektin sta za zdravljenje infestacij s paraziti že odobrena ločeno.
English: This means that it kills parasites present on the skin or in the fur or ears of animals, such as fleas, ticks and ear mites.
Slovenian: To pomeni, da ubije parazite na koži, v dlaki ali ušesih živali, kot so bolhe, klopi in ušesne garje.